IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma: https://lnkd.in/gjTqW2C5
IDEAYA Biosciences
Biotechnology Research
South San Francisco, California 14,674 followers
Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision medicine targets.
About us
IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.
- Website
-
https://www.ideayabio.com
External link for IDEAYA Biosciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- Synthetic Lethality and Precision Medicine
Locations
-
Primary
Get directions
7000 Shoreline Court
350
South San Francisco, California 94080, US
Employees at IDEAYA Biosciences
Updates
-
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers: https://lnkd.in/gvrSZgjj
-
-
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024: https://lnkd.in/gWfiRv82
-
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer: https://lnkd.in/g7V9FUxp
-
-
IDEAYA Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor: https://lnkd.in/gyBrT3zz
-
-
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/gaARpkFa
-
IDEAYA Announces Participation in Upcoming December 2024 Investor Relations Events: https://lnkd.in/gJUSavDA
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
media.ideayabio.com
-
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/g8bKuQ75
-
IDEAYA Appoints Stu Dorman as Chief Commercial Officer: https://lnkd.in/gNPJMtXM
-
-
IDEAYA Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day: https://lnkd.in/gwhju2jY
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
media.ideayabio.com